HLA - B5 (b*51/52), in Visit Clinic

HLA-B51 positive means a person carries the HLA-B51 human leukocyte antigen allele. It indicates increased genetic susceptibility to Behçet’s disease but is not diagnostic by itself. It’s more common in some ethnic groups and may be linked with higher risk of certain complications (for example, eye involvement). Clinicians interpret it alongside symptoms and other tests when evaluating patients.

A positive HLA‑B5 result means you carry a specific HLA genetic marker that is associated with increased susceptibility to Behçet’s disease. It is not diagnostic on its own—many carriers never develop the condition. Clinical symptoms (recurrent oral/genital ulcers, eye inflammation, skin lesions) and specialist assessment are required. Discuss the result with your doctor for further evaluation and monitoring.

HLA-B5 (especially the B*51 allele) is most strongly associated with Behçet’s disease — an inflammatory multisystem vasculitis causing recurrent oral and genital ulcers, eye inflammation, skin lesions, and arthritis. HLA-B5 positivity increases susceptibility and may relate to more severe, particularly ocular, involvement. It can support diagnosis alongside clinical criteria but is not solely diagnostic.

HLA‑B52 is not a direct cause but is strongly associated with increased risk of certain autoimmune conditions—most notably Takayasu arteritis (especially in East Asian populations) and ulcerative colitis. It’s also linked to higher susceptibility to some other autoimmune vasculitides and inflammatory bowel disease phenotypes. Presence of HLA‑B52 indicates genetic predisposition, not certainty of developing these diseases.

HLA-B*51 is strongly associated with Behçet’s disease: individuals carrying this allele have higher risk of developing recurrent oral and genital ulcers, uveitis, skin lesions and systemic vasculitis. The allele correlates with increased susceptibility and often more severe or ocular-involving disease, particularly in populations along the historic Silk Road. It is a genetic risk factor, not a definitive diagnostic marker.

HLA‑B positive means a person carries one or more HLA‑B antigens (class I human leukocyte antigen) on their cells. These proteins present peptide fragments to immune cells, affecting transplant compatibility, susceptibility to certain autoimmune conditions (for example HLA‑B27 with ankylosing spondylitis) and risk of some drug hypersensitivities (e.g., HLA‑B*57:01 with abacavir). HLA typing is done by blood test.